Evidence map›Paper›PMID 33853812›Full record

ArticleBMJ case reports2021

Acute lung toxicity by nitrofurantoin.

Eliana Milazzo, Gabriela Orellana, Adriana Briceño-Bierwirth, Vamsi Kiran Korrapati

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eliana MilazzoDepartment of Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Odessa, Texas, USA Eliana.milazzo@ttuhsc.edu.ORCID http://orcid.org/0000-0002-8223-2838
Gabriela OrellanaDepartment of Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Odessa, Texas, USA.
Adriana Briceño-BierwirthDepartment of Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Odessa, Texas, USA.
Vamsi Kiran KorrapatiDepartment of Internal Medicine, Midland Inpatient Medical Associates, Midland Memorial Hospital, Midland, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitrofurantoin is a synthetic derivative of imidazolinedione, used to treat uncomplicated urinary tract infections. It acts by inhibiting bacterial DNA, RNA and cell wall protein synthesis. It is used prophylactically as a urinary anti-infective agent against most gram-positive organism and for long-term suppression of infections. Nitrofurantoin-associated pulmonary injuries occur in 1% of patients, presenting with dyspnoea and dry cough, and it can mimic interstitial lung disease. We present a case of an 81-year-old woman with shortness of breath and cough 3 days after initiation of nitrofurantoin. CT of the chest revealed bilateral pleural effusion and extensive pulmonary interstitial prominence, suggesting pulmonary fibrosis. According to the Naranjo Adverse Drug Reaction Probability Scale score of 6, it was determined that nitrofurantoin was the probable cause, and immediate cessation of the medication showed a marked clinical improvement and resolution after 10 days.

Indexed as

Drug-Related Side Effects and Adverse ReactionsUrinary Tract InfectionsAged, 80 and overAnti-Infective Agents, UrinaryFemaleHumansLungNitrofurantoinAnti-Infective Agents, UrinaryNitrofurantoinrespiratory systemunwanted effects / adverse reactions

Identifiers

PMID33853812
PMCPMC8054053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.